Zobrazeno 1 - 1
of 1
pro vyhledávání: '"inetetamab/cipterbin"'
Publikováno v:
Open Life Sciences, Vol 18, Iss 1, Pp 209-49 (2023)
Most patients with metastatic breast cancer or gastric cancer who are treated with trastuzumab, an anti-HER2 monoclonal antibody, become refractory to the drug within a year after the initiation of treatment. Although the combination of trastuzumab w
Externí odkaz:
https://doaj.org/article/6bf403e8cf594787b2473d82feda4b28
